| scholarly article | Q13442814 |
| P50 | author | Alexander Shvalov | Q59657053 |
| Vera Morozova | Q85002403 | ||
| P2093 | author name string | Viktoriya Dubrovskaya | |
| Nina Tikunova | |||
| Nikolai Bormotov | |||
| Yana Khlusevich | |||
| Aleksandr Laman | |||
| Eugeni Belanov | |||
| Fedor Brovko | |||
| Tatiana Yun | |||
| P2860 | cites work | An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge | Q24535956 |
| Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox | Q24623839 | ||
| Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus | Q27472711 | ||
| Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo | Q27486404 | ||
| Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library | Q30700446 | ||
| Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display | Q30820969 | ||
| By-passing immunization. Human antibodies from V-gene libraries displayed on phage | Q30831419 | ||
| A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo | Q33285591 | ||
| Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. | Q33350700 | ||
| Isolation of scFvs that inhibit the NS3 protease of hepatitis C virus by a combination of phage display and a bacterial genetic screen | Q33474391 | ||
| Isolation and characterization of human neutralizing antibodies to rabies virus derived from a recombinant immune antibody library | Q33475380 | ||
| Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner | Q33489925 | ||
| Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice | Q33527414 | ||
| A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. | Q33624420 | ||
| Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo | Q33801656 | ||
| Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model | Q33967713 | ||
| Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. | Q33987410 | ||
| Isolation of high affinity human antibodies directly from large synthetic repertoires. | Q34331136 | ||
| Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections | Q34447009 | ||
| Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus | Q34478724 | ||
| Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. | Q34502997 | ||
| Clinical efficacy of intramuscular vaccinia immune globulin: a literature review | Q35912417 | ||
| Human monkeypox infection: a family cluster in the midwestern United States | Q35925250 | ||
| Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model | Q35948047 | ||
| Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate | Q36141610 | ||
| Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine | Q36498147 | ||
| Neutralization of animal virus infectivity by antibody | Q36827854 | ||
| Therapeutic and prophylactic drugs to treat orthopoxvirus infections | Q37009973 | ||
| Inhibition of monkeypox virus replication by RNA interference | Q37422402 | ||
| Response to smallpox vaccine in persons immunized in the distant past | Q40556248 | ||
| Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox | Q40579847 | ||
| Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections | Q40666918 | ||
| Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1 | Q41816066 | ||
| Variola and camelpox virus-specific sequences are part of a single large open reading frame identified in two German cowpox virus strains. | Q42646485 | ||
| Chimeric antibodies against tick-borne encephalitis virus. | Q42997595 | ||
| The detection of monkeypox in humans in the Western Hemisphere. | Q43217764 | ||
| Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires | Q47433216 | ||
| Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. | Q51838980 | ||
| Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. | Q52594194 | ||
| Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes | Q70141457 | ||
| P433 | issue | 1 | |
| P921 | main subject | phage display | Q896217 |
| P304 | page(s) | 141-150 | |
| P577 | publication date | 2011-09-24 | |
| P1433 | published in | Virus Research | Q15749215 |
| P1476 | title | The neutralizing human recombinant antibodies to pathogenic Orthopoxviruses derived from a phage display immune library | |
| P478 | volume | 163 |
Search more.